Skip to main content

Table 4 shows the answers of the survey regarding the initial study synopsis of the DEGRO Prostate Cancer expert panel. The patient cohort was estimated as cT2-cT3 stage, Gleason-Score 7b-8, PSA < 40 ng/ml and cN0 cM0 stage

From: Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

  In total Fully agree
(1)
partially agree
(2)
neutral
(3)
partially disagree
(4)
fully disagree
(5)
No answer
Moderate hypofractionated radiotherapy (regardless of focal dose escalation) will be the standard of care for the envisaged patient cohort in 10 ten years 9 56% 33% 11% 0% 0% 0%
Patients in the envisaged cohort will not be treated with moderate hypofractionated radiotherapy in 10 years, since all parients will be treated with SBRT 9 0% 0% 44% 44% 11% 0%
Patients in the envisaged cohort will not be treated with moderate hypofractionated radiotherapy in 10 years, since all parients will be treated with brachytherapy (at least for dose escalation purposes) 9 11% 0% 0% 33% 56% 0%
Patients with cT3a stage should be excluded in the clinical trial 9 0% 0% 22% 11% 67% 0%
Patients with cT3b stage should be excluded in the clinical trial 9 33% 11% 22% 11% 22% 0%
Patients with gleason score 9 should be excluded in the clinical trial 8 50% 13% 0% 0% 13% 25%
Duration of 6 months androgen deprivation therapy for unfavorable intermediate risk and 18 months for high risk patients is adequate 8 13% 13% 50% 0% 13% 13%
Elective lymph nodes shold be treated in patients with cN0 stage according to PET and MRI but high risk of nodal disease 7 0% 29% 29% 0% 43% 0%
Urethra should be delineated and spared 8 50% 13% 38% 0% 0% 0%
The proposed dose concept (62 Gy to the whole prostate with focal boost up to 75 Gy in 20 fractions in the experimental arm) seems reasonable 10% 10% 20% 60% 0% 0% 10%